miR-30d-5p promotes beta cell recovery and immunomodulation in type 1 diabetes - Takeaways - MDSpire

miR-30d-5p promotes beta cell recovery and immunomodulation in type 1 diabetes

  • By

  • Laia Gomez-Muñoz

  • David Perna-Barrull

  • Dagmar Klein

  • Silvia Alvarez-Cubela

  • Gerard Godoy-Tena

  • Daniel A Cook

  • Catalina Quimper Voto-Bernales

  • Mayur Doke

  • Marta Murillo

  • Aina Valls

  • Ricardo Luis Pastori

  • Juan Dominguez-Bendala

  • Marta Vives-Pi

  • June 2, 2026

  • 0 min

Share

  • 1

    miR-30d-5p is upregulated during the partial remission phase of type 1 diabetes, suggesting its role in immune regulation and beta cell recovery.

  • 2

    Transfection of human pancreatic slices with miR-30d-5p enhances insulin secretion and promotes the emergence of insulin-producing cells.

  • 3

    In non-obese diabetic mice, treatment with miR-30d-5p delays diabetes onset, indicating its potential immunomodulatory and beta cell-protective effects.

  • 4

    miR-30d-5p increases the expression of inhibitory molecules in human T lymphocytes, modulating interferon-gamma secretion.

  • 5

    The study highlights the complex interplay between immune and epigenetic mechanisms during the partial remission phase in type 1 diabetes.

Original Source(s)

miR-30d-5p promotes beta cell recovery and immunomodulation in type 1 diabetes

  • by Laia Gomez-Muñoz, David Perna-Barrull, Dagmar Klein, Silvia Alvarez-Cubela, Gerard Godoy-Tena, Daniel A Cook, Catalina Quimper Voto-Bernales, Mayur Doke, Marta Murillo, Aina Valls, Ricardo Luis Pastori, Juan Dominguez-Bendala, Marta Vives-Pi

  • June 2, 2026

Related Content

Metformin’s Potential Role in Posterior Capsule Opacification

Common diabetes therapy reaches intraocular lens tissue and may help limit PCO, says newly published data

  • March 30, 2026

  • 3 min
Estimation of lifetime benefits from the optimization of secondary prevention in patients with established atherosclerotic cardiovascular disease

Anti-Diabetic Retinopathy Molecular Mechanism of Dihuang Yinzi: Insights from Network Pharmacology, Metabolomics, and Microbiome Analysis